Sangamo Therapeutics(SGMO) - 2025 Q2 - Quarterly Results

RICHMOND, California, August 7, 2025 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2025 financial results. "I'm proud of the progress achieved across our pipeline this quarter. The announcement of positive topline results from our registrational STAAR study in Fabry disease represented a significant step forward on our path towards commercialization for this important program," said Sandy Macrae, Chief Executive Officer ...